Why Amylyx Pharmaceuticals Stock Skyrocketed Today
GLP-1 drugs aren't just for weight loss.
Overview
Shares of Amylyx Pharmaceuticals (NASDAQ: AMLX) surged on Tuesday after the biotechnology company announced positive clinical trial results for its investigational glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide.
Image source: Getty Images.
Roughly 8% of the 160,000 people in the U.S. who have had the two most common types of bariatric (weight loss) surgeries -- sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB) -- suffer from chronic hypoglycemia, or low blood sugar.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.